Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MediGene and Celltrion have signed a binding memorandum of understanding for the co-development and commercialization of an anti-L1 monoclonal antibody for the treatment of cancer.
Subscribe to our email newsletter
Under the terms of the agreement, the companies will share responsibilities for development and commercialization of the anti-L1 monoclonal antibody (L1 MAb). Celltrion will conduct process development and manufacturing of the product and will have exclusive responsibility for development and commercialization of the L1 MAb in Asia, including Japan.
Celltrion will also have an option for global manufacturing rights to supply Phase III and commercial material. MediGene retains the rights for the development and commercialization of the product in Europe, US and the remaining areas.
Peter Heinrich, CEO of MediGene, said: “MediGene and Celltrion have a shared vision for the development and commercialization of the L1 MAb in a range of potential cancer indications, with the lead indication being ovarian cancer.
“We are confident in the potential of this product as a novel means of treating cancer in humans, an area where there is still a high unmet medical need. Celltrion as one of the leading biopharmaceutical manufacturing companies worldwide will be an excellent partner for this highly innovative drug candidate.”